(HealthDay) -- A novel approach using a bioengineered mobilized cellular product enriched with hematopoietic stem cells (HSCs) and tolerogenic graft facilitating cells (FCs) in combination with nonmyeloablative conditioning ...
Mar 8, 2012
0
0
(HealthDay)—For adults with immune thrombocytopenia, the addition of mycophenolate mofetil to a glucocorticoid for first-line treatment is associated with fewer treatment failures and higher response rates than glucocorticoid-only ...
Sep 2, 2021
0
5
In updated guidelines issued by the American Academy of Dermatology and published online Nov. 7 in the Journal of the American Academy of Dermatology, recommendations are presented for use of phototherapy and systemic therapies ...
Nov 16, 2023
0
0
(HealthDay)—Heart transplant (HT) recipients with COVID-19 infection have a case fatality rate of 25 percent, according to a study published online May 13 in JAMA Cardiology.
May 14, 2020
0
0
New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, demonstrated that withholding mycophenolate mofetil for at least 10 days significantly increased antibody response ...
Nov 8, 2022
0
2
New research indicates that mycophenolate mofetil, a drug that is usually used to prevent rejection after kidney, heart or liver transplant, seems safe and effective in treating autoimmune hepatitis (AIH), a serious chronic ...
Mar 21, 2016
0
1
(HealthDay)—For patients with pemphigus vulgaris, rituximab is superior to mycophenolate mofetil for producing sustained complete remission at 52 weeks, according to a study published online May 19 in the New England Journal ...
May 19, 2021
0
2
